Skip to content
Open menu Close menu

Dr Khaled H Assi

PositionSenior Lecturer in Pharmaceutical Sciences
Location4.01 Norcroft Building
DepartmentSchool of Pharmacy and Medical Sciences
Telephone+44 (0) 1274 234703
LinkedInVisit my LinkedIn profile

Research Interests (key words only)

Formulations for inhaled products including dry powder, nanosuspension and nanoemaulsion for both dry powder inhalers and nebulisers; Dissolution of inhaled drugs; In vivo, in vitro, ex vivo evaluation of inhaled drugs and inhalation techniques; Relative lung and systemic bioavailability of inhaled drugs; Development and validation of pharmaceutical and bioanalytical HPLC assay methods.

PhD Supervision

10 students successfully supervised to completion. Current students are:

  • Fatima Aloum
  • Muthana Obeed
  • Rahaf Oum
  • Syed Mazhar

Teaching and Supervisory Responsibilities

MSc Pharmaceutical Technology and Medicines Control Module leader:

  • Process Analytical Technologies and Quality by Design
  • Quality Assurance and Medicine Safety

MSc Research Project Module team member:

  • Critical Appraisal of a Current Topic in Pharmaceutical Sciences

MPharm Unit lead:

  • Foundation Studies for Pharmacy 2, Unit 4- Life Cycle of a Medicine
  • Transport 1, Unit 6

Unit team member:

  • Transport 1, Unit 1
  • Transport 2, Unit 2
  • Patient Centred Care, Unit 2

Administrative Responsibilities

  • Programme Leader for the MSc Pharmaceutical Technology and Medicines Control
  • MSc Pharmaceutical Technology and Medicines Control admission tutor
  • MSc and MPharm personal academic tutor
  • Member of the School of Pharmacy and Medical Sciences Learning and Teaching committee
  • Member of the Faculty of Life Sciences Learning and Teaching committee


Dr Khaled H Assi obtained his BSc in the Sciences of Chemistry in 1994 and was awarded the PhD in pharmaceutical analysis by the University of Bradford, in 1999.

He then took up a post doctoral post at university of Bradford between 1999-2001 working on the inhaled therapies. His post doctoral program was extended for one more year through an awarded grant from Glaxo SmithKline joint with Professor H Chrystyn.

In 2002, he was accepted a research fellowship at Bradford School of Pharmacy. Dr Assi was appointed as a Lecturer at the Bradford School of Pharmacy, in July 2004 and has continued developing his research in the inhaled therapies area. In this position he is teaching the pharmacy and pharmaceutical management students at different levels. The modules he delivers cover the area of pharmaceutical analysis, Quality assurance and quality control of pharmaceuticals.

He is also active in the research. His research interests cover the inhalation therapies and developing of pharmaceutical and bioanalytical assay methods for the determination of inhaled drugs in biological fluids to measure the lung deposition.

He has published over 40 Conference and Journal papers. He supervised 10 completed PhD projects and currently supervising 5 PhD students. He was an internal examiner for many PhD theses and also he is a reviewer for several international journals.

Study History

  • Fellowship of the Higher Education Academy, 2016, University of Bradford
  • PhD in Pharmaceutical Analysis, 1999, University of Bradford
  • BSc in Sciences of Chemistry, 1994, University Of Al-Quds, Jerusalem

Professional History

  • 2005 – 2016: Lecturer in Medicine Development and Pharmaceutical Sciences, School of Pharmacy, University of Bradford, UK
  • 2002 – 2004: Research fellow in Pharmaceutical Chemistry, School of Pharmacy University of Bradford
  • 1999 – 2002: Postdoctoral research fellow investigating In-vitro & In-vivo Aspects of Dry Powder Inhalers, at the School of Pharmacy, University of Bradford, UK.

Professional Activities

  • Member of the Aerosol Society
  • Member of the Editorial Advisory Board of the Journal of BioImpacts

Research Areas

My main research area lie in the field of drug delivery to the lung, this encompass formulation development for inhalation products. The work involves the development of new formulations for inhaled products including dry powder, nanosuspension and nanoemaulsion for both dry powder inhalers and nebulisers. It also involves selecting a suitable inhalation device for doses of dry powder inhalers and nebulised solutions based on the targeted peripheral lung areas for both locally and systemically acting pharmaceuticals.

I also have research interest in the following:

  • Urinary drug excretion to identify lung and systemic deposition following inhalation
  • Evaluate the bioequivalence of inhaled drugs and inhalation techniques
  • Determination of the in vitro characteristics of inhaled products and assessing the in vitro quality of the dose emitted from inhalation systems (dry powder inhalers [DPIs], metered dose inhalers [MDIs] and nebulisers) and in the determination of the resistance characteristics and comparative product features of various marketed DPIs to identify the optimum inhalation flow rate and appropriate DPI for different patients.

In addition to the inhaled therapy I have research in the development of pharmaceutical and bioanalytical assay methods. This includes the optimisation and validation of bioanalytical techniques for qualitative and quantitative determination of inhaled drugs and its metabolites in aqueous and biological fluids for bioequivalence and pharmacokinetic studies.


M. Mashat, B.J. Clark, K.H. Assi, H. Chrystyn., (2017). “Assessment of recent nebulizer delivery systems using urinary pharmacokinetics method and aerodynamic characteristics of TOBI® nebulized dose following inhalation’’, Journal of Drug Delivery Science and Technology 39 (2017) 428-434.

S.M. Shah, F. Ullah, S. Khan, S.M. Shah, M. de Matas, Z. Hussain, M.U. Minhas, N.M. AbdEl-Salam, K.H. Assi, M. Isreb., (2016), “Smart nanocrystals of artemether: fabrication, characterization, and comparative in vitro and in vivo antimalarial evaluation”, Drug Des Devel Ther, (10), 3837-3850.

M. Mashat, B.J. Clark, K.H. Assi, H. Chrystyn., (2016). “In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems’’, Pulmonary Pharmacology & Therapeutics, 37, 37-42.

M. S. Althanyan, Abed-Al Nasser. H, Assi, B.J. Clark, K.H. Assi.,(2016). “Microemulsion High Performance Liquid Chromatography (MELC) for Determination of Terbutaline in Urine Samples’’, Int. J. Pharm. Sci. Rev. Res., 36, 288-292. Impact Factor: 0.65.

M. H. Mashat, B.J. Clark,, K.H. Assi, H. Chrystyn., (2015). “In vitro Performance Assessment of Recent Nebuliser Delivery Systems for Nebulisation of Approved Aerosolised Tobramycin (TOBI) ’’, Journal of Applied Biopharmaceutics and Pharmacokinetics, 3, 34-46.

M.KH. AL-Jammal, Y. Al ayoub, K.H. Assi., (2015). “Development and Validation of Microemulsion High Performance Liquid Chromatography (MELC) Method for the Determination of Nifedipine in Pharmaceutical Preparation’’, Pharmaceutica Analytica Acta, 6, 347.

S.Ibn Yakubua, K.H.Assi, H.Chrystyn., (2013). “ Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen Cascade Impactor with a mixing inlet: The influence of flow and volume’’, International Journal of Pharmaceutics, 455, 213– 218.

M. S. Althanyan, B.J. Clark, J. Hanaee, K.H. Assi., (2013). “Development of a Microemulsion High Performance Liquid Chromatography (MELC) Method for Determination of Salbutamol in Metered Dose Inhalers’’, BioImpacts , 3 ( 1 ), 37 – 42

Abdelrahim, M.E., Assi, K.H. and Chrystyn, Henry (2011) Dose emission and aerodynamic characterization of the terbutaline sulphate dose emitted from a Turbuhaler at low inhalation flow. Pharmaceutical Development and Technology. ISSN 1083-7450 (In Press)

M. S. Althanyan, K.H. Assi, B.J. Clark, J. Hanaee“Microemulsion high performance liquid chromatography (MELC) method for the determination of terbutaline in pharmaceutical preparation”, J. Phar. Biomed. Anal; 55 (2011) 397-402.

Abdelrahim, Mohamed E., Assi, Khaled H. and Chrystyn, Henry (2011) “Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion”,. British Journal of Clinical Pharmacology, 71 (4). pp. 608-610. ISSN 1365-2125

D.K. Nadarassan, H Chrystyn, BJ Clark, KH Assi “Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor”, European Journal of Pharmaceutical Sciences 39 (2010) 348–354.

Alaboud, A., Assi, K.H. and Chrystyn, Henry (2010) “In vitro characterization of the emitted dose from the foradil aerolizer to identify the influence of inhalation flow, inhilation volume and the number of inhalations per dose”,. Respiratory drug delivery, 3. pp. 803-806.

Mashat M, Clark BJ, Chrystyn H, Assi KH “Development and validation of HPLC method for the determination of tobramycin in urine samples post-inhalation using pre-column derivatisation with fluorescein isothiocyanate”, Journal of Chromatography B, 869 (2008) 59-66.


Share this